SARS nucleic acids, proteins, antibodies, and uses thereof

Details SARS nucleic acids, proteins, antibodies, and uses thereof SARS nucleic acids, proteins, antibodies, and uses thereof

2008-07-08

2008-07-08

Lucas, Zachariah (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S388100, C530S388800, C530S388300

Reexamination Certificate

active

07396914

ABSTRACT:
Codon-optimized nucleic acids, polypeptides, and antibodies are described herein.

REFERENCES:
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 2006/0240515 (2006-10-01), Dimitrov et al.
patent: WO 92/03918 (1992-03-01), None
patent: WO 94/25585 (1994-11-01), None
patent: WO 98/24884 (1998-06-01), None
Kashmiri S. et al. “SDR grafting—a new approach to antibody humanization”. Methods. May 2005;36(1):25-34.
Tamura M. et al “Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only”. J Immunol. Feb. 1, 2000;164(3)1432-41.
Altman, L. “More SARS cases are reported; virus found to persist in patients.” Retrieved from the Internet: www.nytimes.com/2003/05/02/science/sciencespecial/02INFE.thml?th . . . Retrieved on May 2, 2003. 3 pages.
Altman, L. “Study in Hong Kong suggests a higher rate of SARS death.” Retrieved from the Internet: www.nytimes.com/2003/05/07/science/sciencespecial/07INFE.html?th. Retrieved on May 7, 2003. 3 pages.
American Association of Blood Banks. “FDA recommends deferrals for SARS exposure.” Retrieved from the Internet: www.aabb.org/Pressroom/In—the—News/wnsars041803.thm. Retrieved on Apr. 23, 2003. 2 pages.
Ang, A. “WHO raises SARS death rate as death toll tops 500; New study suggests SARS may have been in humans longer than previously thought.”AP Worldstream2003 3 pages.
Ang, A. “China's tests of SARS vaccine shift to humans.” Retrieved from the Internet: www.philly.com/mld/inquirer
ews
ation/7342856.thm?template=contentModules/printstory. Retrieved on Nov. 25, 2003.
Associated Press, et al. “New SARS travel warning issued.” Retrieved from the Internet: www.msnbc.com
ews/885653.asp?vts=-42320030855. Retrieved on Apr. 23, 2003. 7 pages.
Associated Press. “China to begin testing SARS vaccine.” Retrieved from the Internet: www.msnbc.com/m/pt/printthis—main?storyID=997544. Retrieved on Nov. 25, 2003. 2 pages.
Associated Press. “Bone ailment found in some SARS survivors.” Retrieved from the Internet:www.miami.com/mld/miamiherald/7221736.htm?template=contentModules/prinstory.jsp. Retrieved on Nov. 10, 2003. 1 page.
Babcock, G., et al. “Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor.”J Virol. May 2004;78(9):4552-60.
Boeckh, M., et al. “Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.”J Infect Dis. Aug. 1, 2001;184(3):350-4.
Booth, C., et al. “Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.”JAMA. Jun. 4, 2003;289(21):2801-9.
Bonavia, A., et al. “Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E.”J Virol. Feb. 2003;77(4):2530-8.
Breslin, J., et al. “Human coronavirus 229E: receptor binding domain and neutralization by soluble receptor at 37 degrees C.”J Virol. Apr. 2003;77(7):4435-8.
Broder, J. “Aggressive steps help U.S. avoid SARS brunt.” Retrieved from the internet: www.nytimes.com/2003/05/05
ational/05SARS.html?th. Retrieved on May 5, 2003. 3 pages.
Brown, E., et al. “Comparative analysis of the SARS coronavirus genome: a good start to a long journey.” Published online May 9, 2003. image.thelancet.com/extras/03cmt124web.pdf.
Bukreyev, A., et al. “Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.”Lancet. Jun. 26, 2004;363(9427):2122-7.
Burns, R. “WHO raises SARS death rate as death toll tops 500: China says situation grim.”AP Worldstream2003, 5 pages.
Callow, K., et al. “The time course of the immune response to experimental coronavirus infection of man.”Epidemiol Infect. Oct. 1990;105(2):435-46.
Callow, K. “Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection.”J Hyg(Lond). Aug. 1985;95(1):173-89.
Cavallaro, J., et al. “Community-wide outbreak of infection with a 229E-like coronavirus in Tecumseh, Michigan.”J Infect Dis. Oct. 1970;122(4):272-9.
Centers for Disease Control and Prevention (CDC). “Efficiency of quarantine during an epidemic of severe acute respiratory syndrome—Beijing, China, 2003.”MMWR Morb Mortal Wkly Rep. Oct. 31, 2003; 52(43):1037-40.
Centers for Disease Control and Prevention (CDC). “Prevalence of IgG antibody to SARS-associated coronavirus in animal traders—Guangdong Province, China, 2003.”MMWR Morb Mortal Wkly Rep. Oct. 17, 2003;52(41):986-7.
Centers for Disease Control and Prevention (CDC). “Severe acute respiratory syndrome—Singapore, 2003.”MMWR Morb Mortal Wkly Rep. May 9, 2003;52(18):405-11.
Centers for Disease Control and Prevention (CDC) Press Release. “CDC lab sequences genome of new coronavirus.” Retrieved from the Internet: www.cdc.gov/od/oc/media/pressrel/r030414.htm. Retrieved on Apr. 23, 2003. 2 pages.
Centers for Disease Control and Prevention (CDC). “Update: Severe acute respiratory syndrome—United States, 2003.”MMWR Morb Mortal Wkly Rep. May 2003;52(17):388-91.
Centers for Disease Control and Prevention. “Severe Acute Respiratory Syndrome (SARS) and coronavirus testing—United States, 2003.”JAMA. May 7, 2003;289(17):2203-6.
Centers for Disease Control and Prevention (CDC). “Update: outbreak of severe acute respiratory syndrome—worldwide, 2003.”MMWR Morb Mortal Wkly Rep. Apr. 4, 2003;52(13):269-72.
Champlin, R., et al. “Community respiratory virus infections in bone marrow transplant recipients: the M.D. Anderson Cancer Center experience.”Biol Blood Marrow Transplant. 2001;7 Suppl:8S-10S.
The Chinese SARS Molecular Epidemiology Consortium. “Molecular Evolution of the SARS coronavirus during the course of the SARS epidemic in China.” Published online Jan. 30, 2004. www.sciencemag.org/10/1126/science.1092002. 28 pages.
Collins, A., et al. “Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell—cell fusion.”Virology. Jun. 1982;119(2):358-71.
Collins, A. “Interferon gamma potentiates human coronavirus OC43 infection of neuronal cells by modulation of HLA class I expression.”Immunol Invest. Nov. 1995;24(6):977-86.
Collins, A. “Human coronavirus OC43 interacts with major histocompatibility complex class I molecules at the cell surface to establish infection.”Immunol Invest. Aug. 1994;23(4-5):313-21.
Connor, A., et al. “Comparison of human respiratory syncytial virus A2 and 8/60 fusion glycoprotein gene sequences and mapping of sub-group specific antibody epitopes.”J Med Virol. Feb. 2001;63(2):168-77.
Connor, S. Secrets of SARS virus's lethal mutation unlocked by scientists. Retrieved from the Internet: www.independent.co.uk
ews. Retrieved on Jan. 30, 2004. 2 pages.
Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). Meeting held May 16-17, 2003. WHO/CDS/CSR/GAR. [Abstract].
Corapi, W., et al. “Localization of antigenic sites of the S glycoprotein of feline infectious peritonitis virus involved in neutralization and antibody-depen

Affiliated with

Also associated with

Rating

SARS nucleic acids, proteins, antibodies, and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with SARS nucleic acids, proteins, antibodies, and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and SARS nucleic acids, proteins, antibodies, and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2809287